Nothing to Sneeze At: Viruses Raise Risk of Neurodegenerative Disease
Twelve severe viral illnesses boosted risk up to 15 years after infection.
ALL NEWS
6566 RESULTS
Sort By:
- Most Recent
- Most Commented
When SORL1 Dimerizes in Endosomes, Retromers Recycle APP Faster
SORL1 may form polymers that bind and stabilize the retromer, facilitating the recycling of APP and other substrates.
Not All Bad: Phosphorylated α-Synuclein Modulates Neurotransmission
p-S129syn better binds its synaptic vesicle protein partners than does plain α-synuclein.
In Nasu-Hakola Disease, DAP12-Deficient Microglia Kick Repair into Overdrive
The first study to survey the brain transcriptomes of people with NHD found microglia and astrocytes frantically repairing injury, and narrowing blood vessels.
Did Dementia Patient Care Go Downhill During the COVID Pandemic?
Data from six countries showed prescriptions for antipsychotic drugs rose in 2020, and remain high.
Droplets in the Bucket? Introducing en Masse Single-Synapse RNA-Seq
A new method reveals distinct synaptic states, some tied to amyloidosis, that were not seen in prior nuclear transcriptomic data.
No Accelerated Approval for Donanemab
The FDA turned down Eli Lilly’s application based on insufficient safety data, with fewer than 100 people on the drug for one year.
Ferried Into Brain, TREM2 Antibody Stirs Microglia
A transferrin receptor binding domain helps transport the antibody across the blood-brain barrier. In the brain, it roused microglia and boosted glucose metabolism.
Cryo-EM Resolves Two Aβ40 Fibril Structures Amplified from People with CAA
In one, the N-terminus was highly structured. In the other, the N-terminus was disordered, similar to Aβ peptides found in the brain parenchyma.
Does Double-Stranded RNA From Jumping Genes Mediate Tau Toxicity?
In fly tauopathy model, dsRNA triggers inflammation and neuron death. In Alzheimer’s, dsRNA accumulates in the brain.
2022 Was Good to Basic Research, Too
Last year saw major advances in multi-omics analyses using human tissues, better animal models, deeper functional studies of gene variants, dissections of neuroimmune cell biology, and more.
2022, a Year in Review
Therapeutics research in the field ended on high hopes that lecanemab’s Phase 3 data would carry this anti-Aβ antibody to regulatory approval in country after country in 2023. This wave drew power from progress in biomarker research; but alas, much work remains to be done.
Meddling Microbiome Worsens Tauopathy and Neurodegeneration
Sex and ApoE genotype influenced the function of the millions of microbes that colonize the mouse gut. Short-chain fatty acids appear to carry messages from bacteria to cytokine-producing cells.
And Then There Were Four: A New Meningeal Membrane Discovered
The lymphatic-like membrane blankets blood vessels in the subarachnoid space and harbors immune cells.
U.S. FDA Gives Green Light to Leqembi, aka Lecanemab
Eisai’s anti-amyloid antibody got the nod via the accelerated approval pathway; the company is expected to apply for traditional approval within days.
Current Filters
- Date Range : All x